On this page
What it is
A neuropeptide encoded by the KISS1 gene, acting on the KISS1R receptor. Its discovery reshaped understanding of how puberty and reproductive function are switched on.
How it is proposed to work
Stimulates GnRH neurons in the hypothalamus, which drives LH and FSH release from the pituitary and downstream gonadal steroid production. Because it acts upstream of GnRH, it engages the axis at its physiological starting point rather than bypassing it.
Approved medical uses
None. Kisspeptin has no approved human medical indication in the jurisdictions we track. Any use is outside an approved label.
Human research
Each entry states what the study found and, separately, what it cannot show.
- Controlled human trial2021
Kisspeptin-54 as a test of hypothalamic GnRH neuronal function in men with congenital hypogonadotropic hypogonadism
Finding. Twenty-one men with congenital hypogonadotropic hypogonadism (CHH) and 21 healthy eugonadal men each received an intravenous bolus of GnRH on one occasion and of kisspeptin-54 on another, and were monitored for 6 hours after each neuropeptide. Maximal luteinizing hormone (LH) rise after kisspeptin-54 was significantly greater in the healthy men than in the men with CHH (p < 0.0001), and the authors report that kisspeptin-54 differentiated the two groups more accurately than GnRH did (area under the receiver operating characteristic curve 1.0, 95% CI 1.0-1.0 for kisspeptin-54 versus 0.88, 95% CI 0.76-0.99 for GnRH), with the LH rise of every man with CHH falling below that of every healthy man. Anosmic men with CHH — Kallmann syndrome — showed even lower LH rises after kisspeptin-54 than normosmic men with CHH (p = 0.017), as did men carrying pathogenic or likely pathogenic variants in CHH genes compared with other men with CHH (p = 0.035). The authors conclude that kisspeptin-54 fully discriminated the two groups and could be used to specifically interrogate hypothalamic GnRH neuronal function in patients with CHH.
Limitation. The abstract reports the two groups separately and prints no combined total, so no single participant figure is recorded here. A diagnostic study using a single bolus of each neuropeptide, in men only, with follow-up limited to the six hours after each administration. It is typed as a controlled human trial because the investigators administered the compound against a healthy comparison group, but group membership was fixed by each man's existing CHH diagnosis rather than allocated, and the report describes no blinding and no placebo, so the control is a comparison group and not a randomised arm. It measures how well one administration discriminates hypothalamic dysfunction; it is not evidence for repeated therapeutic use or for any fertility outcome, and the abstract reports no safety or adverse-event outcome in either direction. Funding is recorded in the PubMed record as the Medical Research Council, the Wellcome Trust and the Biotechnology and Biological Sciences Research Council, with no industry sponsor named.
- Randomised controlled trial2023n = 32
Kisspeptin and sexual brain processing in men with hypoactive sexual desire disorder
Finding. In men with hypoactive sexual desire disorder, intravenous kisspeptin-54 significantly modulated brain activity in key structures of the sexual-processing network on whole-brain fMRI while they viewed sexual videos, compared with placebo. Secondary analyses showed increased penile tumescence in response to sexual stimuli and improved behavioural measures of sexual desire, most notably happiness about sex.
Limitation. A single double-blind crossover trial in 32 men at one academic research centre, testing one infusion per visit rather than a course of treatment. The primary endpoint is an imaging signal; the tumescence and desire measures come from secondary analyses. Nothing here shows a durable change in sexual function, and emotional processing was not among the outcomes measured. Widely over-interpreted in community discussion as evidence of a libido treatment.
Preclinical research
Animal and laboratory work. Useful for generating hypotheses; it cannot establish that something works in people.
No preclinical studies catalogued.
Potential safety concerns
- WatchPreliminary
Generally well tolerated in short controlled administration studies. No dataset exists for repeated self-directed use.
- CautionPromising
Continuous rather than pulsatile stimulation of the reproductive axis can cause downregulation — the principle GnRH agonists exploit to suppress the axis deliberately. Self-directed dosing patterns may achieve the opposite of what is intended.
Known interactions and contraindication considerations
- Not characterised outside trial settings.
This list is not exhaustive and is not a substitute for a clinician reviewing your full medication history.
Regulatory status
Status is shown per jurisdiction and is accurate only as of the date stated. Where a compound is approved, the approval is bound to a specific formulation, manufacturer and indication — shown in the detail column.
| Jurisdiction | Standing | Detail |
|---|---|---|
United States FDA | Unapproved / investigational as of 1 Jun 2026 | Investigational. No marketing authorisation. |
European Union EMA | Unapproved / investigational as of 1 Jun 2026 | Investigational. No marketing authorisation. |
India CDSCO | Unapproved / investigational as of 1 Jun 2026 | Not approved for human use. |
How it is being used
What the grey community actually runs, the reasoning they give, and our read on whether it follows from known biology. This is observation, not evidence, and not a recommendation.
Libido and reproductive axis stimulation
What is run
Episodic administration, sometimes before anticipated activity, sometimes in short courses aimed at the axis.
Their mechanistic reasoning
That kisspeptin sits upstream of GnRH as the master switch of the reproductive axis, and that neuroimaging work showing altered activity in sexual-processing brain regions demonstrates a libido effect.
Reported in the community’s own terms. Not our position.
Stacked with
- hCG or gonadorelin—Combined in axis-support protocols, stacking agents that act at different points.
Regimen shape
- Dose
- figure withheld
- Scale
- Microgram-scale
- Route
- Subcutaneous injection
- Frequency
- Episodic, or short courses
- Timing
- Ahead of anticipated activity in libido-oriented use
- Duration
- Not well defined by any convention
Our read
The upstream role is genuine and important science. The libido claim rests heavily on a very small neuroimaging study, and altered brain activation on a scan is a long way from an effect someone notices. This is a clear case of a real finding being carried much further than it can bear. There is also a pharmacological trap: continuous stimulation of this axis downregulates it, which is the principle GnRH agonists exploit deliberately to suppress reproduction.
What the community reports
The comparison is between how sure the community is and how much is actually known — evidence strength, not direction. A compound can have solid research that came out negative.
Interest is driven largely by press coverage of a small neuroimaging study rather than by user experience. Actual reports are thin and inconsistent, which is itself informative.
Commonly reported as helping
- Increased libido, reported by a minority
- Improved sense of wellbeing, reported vaguely
Also reported, when it goes wrong
- Most reports describe no noticeable effect
- Very short duration of any effect noticed
- Confusion about dosing patterns, with little convention to follow
Why these reports can mislead
Enthusiasm here is downstream of media coverage rather than of user experience, which is an unusual pattern and worth noticing. When reports are this sparse and this mixed for something people expected to work, the honest reading is that it probably does not do much at these patterns of use.
Direct quotations are not published here yet. We will only carry verbatim reports once they are sourced, dated and checked — an unattributed quote is a testimonial, and testimonials are exactly what this section exists to replace.
Watch for, in this use specifically
- Dosing patterns that approach continuous exposure may suppress the axis rather than stimulate it.
- No dataset exists for repeated self-directed use.
Active clinical trials
No registered trials currently tracked for Kisspeptin.
What remains unknown
The questions that would change our assessment if they were answered.
- Do the imaging findings correspond to any effect a person would notice?
- What dosing pattern stimulates rather than downregulates the axis over time?
- Is there a therapeutic role, or is its value mainly diagnostic?
References
- 1.Abbara A, Eng PC, Phylactou M, et al. Kisspeptin-54 Accurately Identifies Hypothalamic Gonadotropin-Releasing Hormone Neuronal Dysfunction in Men with Congenital Hypogonadotropic Hypogonadism. Neuroendocrinology. 2021.PMID 33227799doi
- 2.Mills EG, Ertl N, Wall MB, et al. Effects of Kisspeptin on Sexual Brain Processing and Penile Tumescence in Men With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial. JAMA Netw Open. 2023.PMID 36735255doi
Editorial change history
When we change a grade or a regulatory note, we log it here rather than editing quietly.
Dossier created.
Spotted something wrong? Tell us — we publish corrections.